Takeda to evaluate Crescendo Biologics’ Humabodies
Crescendo Biologics has announced that Takeda is planning to evaluate the application of its recently licensed Humabodies, for the development of novel CAR-T therapeutics.
Read More
Tag: humabodies
Takeda licenses Crescendo’s Humabodies
Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
